Results 61 to 70 of about 326,497 (313)

Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function

European Journal of Heart Failure, EarlyView.
Improving clinical translation of mitoprotective therapies. 31P MRI, phosphorus‐31 magnetic resonance imaging; hiPSC‐CM, human‐induced pluripotent stem cell‐derived cardiomyocyte; IHD, ischaemic heart disease. Abstract Acute myocardial infarction (MI) remains a major cause of death and disability worldwide.
Melanie Paillard, Mahmoud Abdellatif, Ioanna Andreadou, Christian Bär, Luc Bertrand, Bianca J.J.M. Brundel, Gemma Chiva‐Blanch, Sean M. Davidson, Dana Dawson, Fabio Di Lisa, Paul Evans, Zoltan Giricz, Derek J. Hausenloy, Petra Kleinbongard, Frank Lezoualc'h, Elisa Liehn, Christoph Maack, Ange Maguy, Elizabeth Murphy, Cinzia Perrino, Maurizio Pesce, Peter P. Rainer, Katrin Streckfuss‐Bömeke, Matthias Thielmann, Rong Tian, Carlo G. Tocchetti, Jolanda Van Der Velden, Sophie Van Linthout, Serena Zacchigna, Thomas Krieg   +29 more
wiley   +1 more source

Sex-gender and atrial fibrillation treatment in the AntiThrombotic Agents in Atrial Fibrillation (ATA-AF) study

Italian Journal of Medicine, 2016
Atrial fibrillation (AF) is the most common cardiac arrhythmia. This analysis aimed to determine the sex-gender differences in patients with AF enrolled in the observational AntiThrombotic Agents in Atrial Fibrillation (ATA-AF) study.
Cecilia Politi, Tiziana Ciarambino, Letizia Riva, Stefania Frasson, Donata Lucci, Gualberto Gussoni, Lucio Gonzini, Mauro Campanini, Michele Gulizia, Giuseppe Di Pasquale, Giovanni Mathieu, on behalf of ATA-AF Steering Committee and Investigators   +11 more
doaj   +1 more source

Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo‐controlled, crossover trial

European Journal of Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a major healthcare burden with limited treatment options. Geranylgeranylacetone (GGA) has been shown to improve myocardial compliance and endothelial function in preclinical models.
Soufiane Nassiri, Geert H.D. Voordes, Loek van Heerebeek, Daniël H. van Raalte, Marianne C. Verhaar, Daan J. Touw, Merle M. Krebber, Dirk J. Duncker, Etto C. Eringa, M. Louis Handoko, Adriaan A. Voors, on behalf of the RECONNEXT Consortium   +11 more
wiley   +1 more source

Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity

Molecules
Anthracyclines play an irreplaceable role in cancer treatment, although their clinical application is limited due to severe side effects such as arrhythmia, cardiomyopathy, and myocardial infarction.
Rongrong Bai, Zhigao Zhao, Xing Han, Mingying Shang, Guangxue Liu, Feng Xu, Shaoqing Cai   +6 more
doaj   +1 more source

In Silico Assessment of Efficacy and Safety of IKur Inhibitors in Chronic Atrial Fibrillation: Role of Kinetics and State-Dependence of Drug Binding

Frontiers in Pharmacology, 2017
Current pharmacological therapy against atrial fibrillation (AF), the most common cardiac arrhythmia, is limited by moderate efficacy and adverse side effects including ventricular proarrhythmia and organ toxicity.
Nicholas Ellinwood, Dobromir Dobrev, Stefano Morotti, Eleonora Grandi   +3 more
doaj   +1 more source

Immune dysregulation as a key driver of peripartum cardiomyopathy – an exploratory advanced imaging and biomarker study

European Journal of Heart Failure, EarlyView.
Physiological postpartum remodelling and the pathological processes involved in peripartum cardiomyopathy (PPCM). 18FDG‐PET‐CT, 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography; CCL3, chemokine (C‐C motif) ligand 3; CMR, cardiovascular magnetic resonance; CRP, C‐reactive protein; CSF‐1, colony‐stimulating factor 1; CXCL10 ...
Julian Hoevelmann, Charle Viljoen, Tessa Kotze, Carlos Libhaber, Stephen Jermy, Morné Kahts, Fareda Jakoet‐Bassier, Petronella Samuels, Olivia Briton, Lynette Cilliers, Denise Hilfiker‐Kleiner, Peter van der Meer, Michael Böhm, Ntobeko A.B. Ntusi, Karen Sliwa   +14 more
wiley   +1 more source

Interactions between atrial fibrosis and inflammation in atrial fibrillation

Frontiers in Cardiovascular Medicine
Atrial fibrillation (AF) is a complex arrhythmia driven by intricate pathophysiological mechanisms, with atrial fibrosis and inflammation emerging as central players in its initiation and perpetuation.
Zhihua Pang, Ying Ren, Zhuhua Yao
doaj   +1 more source

Arctigenin, a Potential Anti-Arrhythmic Agent, Inhibits Aconitine-Induced Arrhythmia by Regulating Multi-Ion Channels [PDF]

, 2013
Zhenying Zhao, Yongqiang Yin, Hong Wu, Min Jiang, Lou Jian-shi, Gang Bai, Guo-An Luo   +6 more
openalex   +1 more source

Cardio‐microcurrent device treatment for heart failure with reduced ejection fraction: Results from the C‐MIC II open‐label randomized controlled trial

European Journal of Heart Failure, EarlyView.
Efficacy and Safety of C‐MIC Device in Patients with Heart Failure with Reduced Ejection Fraction. 6MWD, 6‐min walk distance; CI, confidence interval; KCCQ‐OSS, Kansas City Cardiomyopathy Questionnaire overall summary score; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
Jesus E. Rame, Jan D. Schmitto, Dragana N. Kosevic, Tamara Kovacevic‐Preradovic, Sasko Jovev, Marija Zdravkovic, Nermir Granov, Tanja Popov, Igor Rudez, Petar Vukovic, Velibor Ristic, Petr Neuzil, Annette Holtdirk, Arjang Ruhparwar, Muhammad Shahzeb Khan, Hans‐Dirk Düngen, Kersten Brandes, Peter Goettel, Johannes Mueller, Faouzi Kallel, Tim Friede, Miodrag Peric, Marat Fudim, Stefan D. Anker, for the C‐MIC II Trial Investigators   +24 more
wiley   +1 more source

A companion to the development of common data elements for Sudden Unexpected Death in Epilepsy (SUDEP)

Epilepsia Open, EarlyView.
Abstract Objective Sudden unexpected death in epilepsy (SUDEP) is a rare but devastating consequence of epilepsy and is the leading cause of death in people with epilepsy. SUDEP is associated with certain characteristics such as the presence of generalized tonic–clonic seizures, duration of epilepsy, and refractoriness to anti‐seizure medications ...
Sloka S. Iyengar, Elaine K. O'Loughlin, Lauren Harte‐Hargrove, Mary Holmay, Laura S. Lubbers, CURE Epilepsy SUDEP Data Standardization Project Steering Committee, Working Group Members, Lisa M. Bateman, Edward Glasscock, Samden Lhatoo, Philippe Ryvlin, Kristina Simeone, Charles Akos Szabo, Gardiner Lapham, David Auerbach, Gordon Buchanan, Jeffrey Buchhalter, Beate Diehl, Elizabeth Donner, Carl Faingold, Daniel Friedman, Christina Gross, Bin Gu, Franck Kalume, David Ryan King, Nuria Lecumberri, Susanne Mueller, William Nobis, Jeffrey Noebels, Terence O’Brien, Manoj Patel, George Richerson, Steven Schachter, Timothy Simeone, Ian Wenker   +34 more
wiley   +1 more source